Autism is a neurodevelopmental condition affecting 1 out of 160 children in the United States
today. Only risperidone has Food and Drug Administration approval for the pharmacologic …

The use of pharmacologic agents as a component of treatment for children and adults with
autism spectrum disorders is common and a substantial body of literature describing …

There are no medications that are specifically marketed for the treatment of autism. There
does exist, however, an extensive body of literature describing both open-label and …

Children with autism spectrum disorder present with a high rate of maladaptive behaviors
and comorbid psychopathology. Psychopharmacologic treatment is frequently used in this …

The substantial increase in the prevalence of autism necessitates that practicing physicians
become more familiar with the presentation of symptoms to increase early diagnoses and …

Although there is no known cure for autism and other pervasive developmental disorders
(PDDs), the appropriate use of medication to control behavioral dysregulation may enhance …

Autism spectrum disorder (ASD) is a heterogeneous neuropsychiatric condition affecting an
estimated one in 36 children. Youth with ASD may have severe behavioral disturbances …

Autism and other pervasive developmental disorders (PDDs) are frequently associated with
dysfunctional behaviors and are characterized by deficits in socialization, communication …

Current evidence-based pharmacotherapy options in children with ASD are very limited, and
many have substantial adverse events. Clinicians should use pharmacotherapy as a part of …

Autism spectrum disorders (ASDs) are a complex group of neurodevelopmental conditions
that develop in early childhood and involve a range of impairments in core areas of social …